These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 10914695)

  • 1. COX-2 specific inhibitors offer improved advantages over traditional NSAIDs.
    Urban MK
    Orthopedics; 2000 Jul; 23(7 Suppl):S761-4. PubMed ID: 10914695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. COX-2-Specific inhibitors--the emergence of a new class of analgesic and anti-inflammatory drugs.
    Everts B; Währborg P; Hedner T
    Clin Rheumatol; 2000; 19(5):331-43. PubMed ID: 11055820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of cyclooxygenase-2-specific inhibitors.
    Cannon GW; Breedveld FC
    Am J Med; 2001 Feb; 110 Suppl 3A():6S-12S. PubMed ID: 11173044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Coxibs: cyclooxygenase-2 inhibitors].
    Turnheim K
    Wien Klin Wochenschr; 2001 Aug; 113(15-16):558-65. PubMed ID: 11571832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the baseline cardiovascular risk profile among hypertensive patients prescribed COX-2-specific inhibitors or nonspecific NSAIDs: data from real-life practice.
    Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC
    Am J Manag Care; 2002 Oct; 8(15 Suppl):S392-400. PubMed ID: 12416789
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of renal-related adverse drug reactions between rofecoxib and celecoxib, based on the World Health Organization/Uppsala Monitoring Centre safety database.
    Zhao SZ; Reynolds MW; Lejkowith J; Whelton A; Arellano FM
    Clin Ther; 2001 Sep; 23(9):1478-91. PubMed ID: 11589261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What have we learned from the large outcomes trials of COX-2 selective inhibitors? The rheumatologist's perspective.
    Hochberg MC
    Clin Exp Rheumatol; 2001; 19(6 Suppl 25):S15-22. PubMed ID: 11695246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual acting anti-inflammatory drugs: a reappraisal.
    Bertolini A; Ottani A; Sandrini M
    Pharmacol Res; 2001 Dec; 44(6):437-50. PubMed ID: 11735348
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Update on clinical developments with celecoxib, a new specific COX-2 inhibitor: what can we expect?
    Geis GS
    Scand J Rheumatol Suppl; 1999; 109():31-7. PubMed ID: 10422544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prevalence of cardiorenal risk factors in patients prescribed nonsteroidal anti-inflammatory drugs: data from managed care.
    Harley C; Wagner S
    Clin Ther; 2003 Jan; 25(1):139-49. PubMed ID: 12637116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. COX-2 inhibitors.
    Brooks PM; Day RO
    Med J Aust; 2000 Oct; 173(8):433-6. PubMed ID: 11090038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. COX-2 selective inhibitors in the treatment of arthritis: a rheumatologist perspective.
    Hochberg MC
    Curr Top Med Chem; 2005; 5(5):443-8. PubMed ID: 15974939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Specific COX-2 inhibitors: prospects of therapy with new analgesic and anti-inflammatory substances].
    Hinz B; Brune K
    Wien Klin Wochenschr; 1999 Feb; 111(3):103-12. PubMed ID: 10093892
    [TBL] [Abstract][Full Text] [Related]  

  • 14. COX-2 inhibitors. Are they nonsteroidal anti-inflammatory drugs with a better safety profile?
    Simon LS
    Gastroenterol Clin North Am; 2001 Dec; 30(4):1011-25, viii. PubMed ID: 11764530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Celecoxib, a selective cyclooxygenase-2 inhibitor for the treatment of rheumatoid arthritis and osteoarthritis.
    Goldenberg MM
    Clin Ther; 1999 Sep; 21(9):1497-513; discussion 1427-8. PubMed ID: 10509845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective cyclooxygenase-2 inhibitors for the treatment of arthritis.
    Fung HB; Kirschenbaum HL
    Clin Ther; 1999 Jul; 21(7):1131-57. PubMed ID: 10463513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclooxygenase-2 specificity and its clinical implications.
    Lefkowith JB
    Am J Med; 1999 May; 106(5B):43S-50S. PubMed ID: 10390127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Celecoxib and rofecoxib. The role of COX-2 inhibitors in dental practice.
    Moore PA; Hersh EV
    J Am Dent Assoc; 2001 Apr; 132(4):451-6. PubMed ID: 11315375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Non-steroidal anti-inflammatory agents with selective inhibitory activity on cyclooxygenase-2. Interest and future prospects].
    Blain H; Jouzeau JY; Netter P; Jeandel C
    Rev Med Interne; 2000 Nov; 21(11):978-88. PubMed ID: 11109595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.
    Silverstein FE; Faich G; Goldstein JL; Simon LS; Pincus T; Whelton A; Makuch R; Eisen G; Agrawal NM; Stenson WF; Burr AM; Zhao WW; Kent JD; Lefkowith JB; Verburg KM; Geis GS
    JAMA; 2000 Sep; 284(10):1247-55. PubMed ID: 10979111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.